This trial is evaluating whether Ixazomib will improve 1 primary outcome and 6 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of Up to 15 months after beginning treatment.
This trial requires 19 total participants across 2 different treatment groups
This trial involves 2 different treatments. Ixazomib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Lymphoma manifests itself as either a relatively large or medium-sized, firm, non-calcified lymph nodule with necrosis. The lymphoid infiltrate is typically composed of mixed lymphocytic, polymorphic or monomorphic cells, varying amounts of which constitute the malignant neoplastic material. This contrasts with the morphological morphology. The malignant neoplastic cells contain non-lymphoblastic elements and are usually pleomorphic. A small percentage may have the morphology of a lymphocyte or a mast cell. We propose that neoplastic malignant cell types within lymphoma contain some malignant neoplastic elements with morphological and proliferative characteristics associated with this type of tumor.
Signs of lymphoma include swollen lymph nodes and other masses, swollen lymph nodes on the neck and in the armpits, coughing up blood, enlarged liver (>5 cm) or spleen (>12 cm), enlarged spleen (<12 cm) and increased blood pressure.\n
Lymphoma develops because of a combination of the two factors, genetic predisposition and environmental trigger. It is a disease whose onset is often gradual and the cause of the disease does not have a well-known trigger. Lymphoma occurs as a result of an abnormal immune system response to cancer or other substances such as radiation, viral agents or some other environmental or chemical trigger. The exact cause of lymphoma is not known. Lymphoma occurs in the body in two types: non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Typically the cause is not well understood but seems to be associated with lifestyle, radiation exposure and infections.
The number of new cancer cases due to lymphoma per year in the United States has doubled from 1970 to the present. The incidence of lymphoma continues to increase. Most patients with lymphoma present with non-Hodgkin's lymphoma. The incidence of Hodgkin ltumor is decreasing. The mean age of diagnosis has declined, with many of these patients diagnosed earlier in the 1970s.
The prognosis in dogs with lymphoma can be difficult to determine and is dependent upon the stage at which the diagnosis is made. Dogs that are still growing at the time of diagnosis are less likely to have a good prognosis and this is also true for dogs younger than 10 years. The long term prognosis for dogs with lymphoma and disease that has been stable but not cured is good and there is usually a complete recovery. These data support the inclusion of dogs with lymphoma in all trials investigating treatments for this disease, especially dogs with non-Hodgkin’s lymphoma but lymphoma in general.
There have been many groundbreaking and fruitful advances for treating this fatal malignancy. Future work will likely focus on understanding the genes involved in progression of the disease. Furthermore, research from various disciplines can hopefully lead to new forms of therapy in the future for patients with lymphoma.
Findings from a recent study show I-IXA significantly increased the percentage of MM cells in vivo and showed MM cell apoptosis in vitro, leading to the induction of an anti-myeloma response. The combination treatment of I-IXA with conventional therapy is being investigated, with promising results from phase I and II studies. Further results are expected from more advanced clinical trials, including trials with patients with refractory and relapsed MM.
Lymphoma in the family seems related to certain alleles of two genes encoding interleukins 2 and 5. The role of these cytokines in lymphoma is supported by the association of an increased risk of B cell lymphoma with chronic inflammation and by the presence of autoimmune disease in patients with sporadic B cell lymphoma. In contrast to previous studies, results of our family-based study suggest that a familial risk of lymphoma is not necessarily associated with a more aggressive sub type of the lymphoma.
The research for lymphoma is still young. Many scientific research findings depend on clinical trials, but it will take a long time before large-scale studies on subjects with lymphoma will provide sufficient data to recommend treatment choices. Patients with advanced disease who received one of the three recently approved agents have shown a significant (30%) median overall response and a high rate of sustained response, which is a positive indicator of long-term survival . In addition, many new trials are still underway  as well as studies exploring the role of targeted therapies such as rituximab and anti-PD-1 combinations .
ixazomib is a novel orally active, clinically active first generation proteasome inhibitor currently undergoing clinical research. The drug is now in its late pre-clinical and clinical development phase in both solid tumors and hematologic malignancies. An effective first generation proteasome inhibitor with favourable safety profile could be a valuable therapeutic option.
There is a broad range of triggers that have been associated with, or are suspected of causing, lymphoma. These risks are grouped under four broad categories: infections, genetic disorders, environmental factors and inflammation. The most frequently cited cause for lymphoma is infection. Chronic viral, fungal and parasitic infections are particularly prone to cause lymphomagenesis. This is especially true for Burkitt’s lymphoma and follicular lymphomas but there are cases that occur for almost 30 of these known cause. The most common cause of non-lymphoid lymphoma is lymphoproliferative disorders. A recent study reports that chronic Epstein-Barr (EBV) was found to be involved in approximately 75% of follicular lymphoma.